Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure

JACC: Heart Failure

Volumn 2, Issue 3, 2014, Pages 260-268

  Ahmad, Tariq ^a,b   Fiuzat, Mona ^a,b   Neely, Benjamin ^b   Neely, Megan L ^b   Pencina, Michael J ^b   Kraus, William E ^a   Zannad, Faiez ^c   Whellan, David J ^d   Donahue, Mark P ^a   Piña, Ileana L ^e   Adams, Kirkwood F ^f   Kitzman, Dalane W ^g   O'Connor, Christopher M ^a,b   Felker, G Michael ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITÉ DE LORRAINE   (France)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g WAKE FOREST UNIVERSITY   (United States)

Author keywords

Biomarker; Heart failure; Mode of death; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GALECTIN 3; ST2 BIOMARKER; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COMORBIDITY; DEATH; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART STRESS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SUDDEN CARDIAC DEATH; BLOOD; CHRONIC DISEASE; CONTROLLED STUDY; DEATH, SUDDEN, CARDIAC; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC HEART FAILURE;

AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; FIBROSIS; GALECTIN 3; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK FACTORS; STRESS, PHYSIOLOGICAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84901658442     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.12.004     Document Type: Article

References (28)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
2. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292:344-350.
3. Korngold E.C., Januzzi J.L., Gantzer M.L., Moorthy M.V., Cook N.R., Albert C.M. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation 2009, 119:2868-2876.
4. Kim H.N., Januzzi J.L. Biomarkers in the management of heart failure. Curr Treat Options Cardiovasc Med 2010, 12:519-531.
5. Tapanainen J.M., Lindgren K.S., Makikallio T.H., Vuolteenaho O., Leppaluoto J., Huikuri H.V. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004, 43:757-763.
6. Havmoller R., Chugh S.S. Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle?. Circ Arrhyth Electrophysiol 2012, 5:237-243.
7. van Kimmenade R.R., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
8. Braunwald E. Heart failure. J Am Coll Cardiol HF 2013, 1:1-20.
9. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301:1439-1450.
10. Whellan D.J., O'Connor C.M., Lee K.L., et al. Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): design and rationale. Am Heart J 2007, 153:201-211.
11. Jason P.F., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
12. Lunn M., McNeil D. Applying Cox regression to competing risks. Biometrics 1995, 51:524-532.
13. O'Connor C.M., Whellan D.J., Wojdyla D., et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail 2012, 5:63-71.
14. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
15. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5:72-78.
16. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
17. Pascual-Figal D.A., Ordonez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
18. Bayes-Genis A., de Antonio M., Vila J., et al. Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3. J Am Coll Cardiol 2013, 63:158-166.
19. Pascual-Figal D.A., Ordonez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
20. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
21. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
22. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:1495-1539.
23. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
24. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscl Thromb Vasc Biol 2013, 33:67-75.
25. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Disc 2008, 7:827-840.
26. Iles L., Pfluger H., Lefkovits L., et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 2011, 57:821-828.
27. Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012, 9:347-359.
28. Piccini J.P., Hellkamp A.S., Whellan D.J., et al. Exercise training and implantable cardioverter-defibrillator shocks in patients With heart failure: results From HFACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). J Am Coll Cardiol HF 2013, 1:142-148.